evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

26 questions · 26 findings · 16 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4 · 15.4%GRADE not reported 0 · 0%Very low 8 · 30.8%Low 6 · 23.1%Moderate 6 · 23.1%High 2 · 7.7%

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).

1 finding from 1 review

Lower blood pressure targets vs standard blood pressure targets

Total serious adverse events · cardiovascular disease with high blood pressure

Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).

1 finding from 1 review

Antihypertensive drug therapy vs placebo or no treatment

Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy

It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Intervention not reported

Total serious adverse events Systolic targets · Diabetes Mellitus with elevated blood pressure

The intervention showed no clear difference in total serious adverse events Systolic targets (low certainty).

1 finding from 1 review

Summary of findings table ‐ Recombinant activated factor VII vs placebo

Serious adverse events by total adverse events · patients with upper gastrointestinal bleeding and liver diseases.

Recombinant human factor VII activated showed no clear difference in serious adverse events by total adverse events compared with placebo (high certainty).

1 finding from 1 review

Diacerein vs placebo

Total number of serious adverse events not measured · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

TACE followed by 3‐DCRT vs chemoembolisation

Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma

It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).

1 finding from 1 review

First‐line thiazides vs calcium channel blockers

Total serious adverse events Duration: 1.75 to 3 years · patients with hypertension

First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review